Oncology Unit, Medical Department, ASST Bergamo Ovest, 24047, Treviglio, Italy.
Medical Oncology Unit, ASST Papa Giovanni XXIII, 24127, Bergamo, Italy.
Future Oncol. 2019 Jan;15(1):33-44. doi: 10.2217/fon-2018-0324. Epub 2018 Nov 9.
We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world.
PATIENTS & METHODS: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics.
No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes.
In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.
我们在意大利进行了一项多中心回顾性队列研究，以描述转移性乳腺癌患者（ESEMPiO）的当前实践情况。
使用描述性统计方法总结基线特征、治疗管理和安全性。
在 ESEMPiO 数据库中登记并在真实实践中治疗的人群中，未发现安全性问题。中位无进展生存期和总生存期分别为 3.2 个月和 10.1 个月。EM 活性在乳腺癌亚型之间相似。
在转移性乳腺癌患者中使用 EM 的“真实世界”环境中，临床医生报告的结果与关键试验报告的结果相当。此外，EM 保持了临床活性和可耐受的安全性。
